Noninferiority trials in second-line treatments of nonsmall cell lung cancer

A systematic review of literature with meta-analysis of phase III randomized clinical trials

Davide Tassinari, Emanuela Scarpi, Sergio Sartori, Fabrizio Drudi, Cinzia Castellani, Federica Carloni, Paola Tombesi, Luigi Lazzari-Agli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND:: To assess the role of the novel second-line treatments in nonsmall cell lung cancer (NSCLC). METHODS:: A systematic review of the literature with meta-analysis of phase III randomized clinical trials (RCTs) was independently performed by 3 authors. All the trials comparing any novel treatment with every-3-weeks docetaxel (3WD) and designed as noninferiority trial were included in the analysis. One-year survival rate (SR) was the primary end point, and quality of life and safety represented the secondary end points. RESULTS:: Four RCTs met the selection criteria. The outcomes of 3355 patients were analyzed in the pooled analysis. No heterogeneity was documented in the primary analysis either including all the trials or analyzing separately gefitinib and the chemotherapeutic alternatives to 3WD. The cumulative odds ratio was 0.927 (P=0.313) for 1-year SR, 0.889 (P=0.323) for the chemotherapeutic alternatives to 3WD and 0.953 (P=0.616) for gefitinib. The experimental arms showed a significant advantage in quality of life in the cumulative analysis (odds ratio=1.623, P=0.01) and in the subgroup of patients treated with gefitinib (odds ratio=1.962, P

Original languageEnglish
Pages (from-to)593-599
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

docetaxel
Phase III Clinical Trials
Non-Small Cell Lung Carcinoma
Meta-Analysis
Randomized Controlled Trials
Odds Ratio
Survival Rate
Quality of Life
Patient Selection
Therapeutics
Safety
gefitinib

Keywords

  • docetaxel
  • erlotinib
  • gefitinib
  • lung cancer
  • pemetrexed
  • second-line treatments
  • topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Noninferiority trials in second-line treatments of nonsmall cell lung cancer : A systematic review of literature with meta-analysis of phase III randomized clinical trials. / Tassinari, Davide; Scarpi, Emanuela; Sartori, Sergio; Drudi, Fabrizio; Castellani, Cinzia; Carloni, Federica; Tombesi, Paola; Lazzari-Agli, Luigi.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 6, 12.2012, p. 593-599.

Research output: Contribution to journalArticle

Tassinari, Davide ; Scarpi, Emanuela ; Sartori, Sergio ; Drudi, Fabrizio ; Castellani, Cinzia ; Carloni, Federica ; Tombesi, Paola ; Lazzari-Agli, Luigi. / Noninferiority trials in second-line treatments of nonsmall cell lung cancer : A systematic review of literature with meta-analysis of phase III randomized clinical trials. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2012 ; Vol. 35, No. 6. pp. 593-599.
@article{ba6dcf47d1f84a4ea6007fb5c89c6ae0,
title = "Noninferiority trials in second-line treatments of nonsmall cell lung cancer: A systematic review of literature with meta-analysis of phase III randomized clinical trials",
abstract = "BACKGROUND:: To assess the role of the novel second-line treatments in nonsmall cell lung cancer (NSCLC). METHODS:: A systematic review of the literature with meta-analysis of phase III randomized clinical trials (RCTs) was independently performed by 3 authors. All the trials comparing any novel treatment with every-3-weeks docetaxel (3WD) and designed as noninferiority trial were included in the analysis. One-year survival rate (SR) was the primary end point, and quality of life and safety represented the secondary end points. RESULTS:: Four RCTs met the selection criteria. The outcomes of 3355 patients were analyzed in the pooled analysis. No heterogeneity was documented in the primary analysis either including all the trials or analyzing separately gefitinib and the chemotherapeutic alternatives to 3WD. The cumulative odds ratio was 0.927 (P=0.313) for 1-year SR, 0.889 (P=0.323) for the chemotherapeutic alternatives to 3WD and 0.953 (P=0.616) for gefitinib. The experimental arms showed a significant advantage in quality of life in the cumulative analysis (odds ratio=1.623, P=0.01) and in the subgroup of patients treated with gefitinib (odds ratio=1.962, P",
keywords = "docetaxel, erlotinib, gefitinib, lung cancer, pemetrexed, second-line treatments, topotecan",
author = "Davide Tassinari and Emanuela Scarpi and Sergio Sartori and Fabrizio Drudi and Cinzia Castellani and Federica Carloni and Paola Tombesi and Luigi Lazzari-Agli",
year = "2012",
month = "12",
doi = "10.1097/COC.0b013e31822dfd13",
language = "English",
volume = "35",
pages = "593--599",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Noninferiority trials in second-line treatments of nonsmall cell lung cancer

T2 - A systematic review of literature with meta-analysis of phase III randomized clinical trials

AU - Tassinari, Davide

AU - Scarpi, Emanuela

AU - Sartori, Sergio

AU - Drudi, Fabrizio

AU - Castellani, Cinzia

AU - Carloni, Federica

AU - Tombesi, Paola

AU - Lazzari-Agli, Luigi

PY - 2012/12

Y1 - 2012/12

N2 - BACKGROUND:: To assess the role of the novel second-line treatments in nonsmall cell lung cancer (NSCLC). METHODS:: A systematic review of the literature with meta-analysis of phase III randomized clinical trials (RCTs) was independently performed by 3 authors. All the trials comparing any novel treatment with every-3-weeks docetaxel (3WD) and designed as noninferiority trial were included in the analysis. One-year survival rate (SR) was the primary end point, and quality of life and safety represented the secondary end points. RESULTS:: Four RCTs met the selection criteria. The outcomes of 3355 patients were analyzed in the pooled analysis. No heterogeneity was documented in the primary analysis either including all the trials or analyzing separately gefitinib and the chemotherapeutic alternatives to 3WD. The cumulative odds ratio was 0.927 (P=0.313) for 1-year SR, 0.889 (P=0.323) for the chemotherapeutic alternatives to 3WD and 0.953 (P=0.616) for gefitinib. The experimental arms showed a significant advantage in quality of life in the cumulative analysis (odds ratio=1.623, P=0.01) and in the subgroup of patients treated with gefitinib (odds ratio=1.962, P

AB - BACKGROUND:: To assess the role of the novel second-line treatments in nonsmall cell lung cancer (NSCLC). METHODS:: A systematic review of the literature with meta-analysis of phase III randomized clinical trials (RCTs) was independently performed by 3 authors. All the trials comparing any novel treatment with every-3-weeks docetaxel (3WD) and designed as noninferiority trial were included in the analysis. One-year survival rate (SR) was the primary end point, and quality of life and safety represented the secondary end points. RESULTS:: Four RCTs met the selection criteria. The outcomes of 3355 patients were analyzed in the pooled analysis. No heterogeneity was documented in the primary analysis either including all the trials or analyzing separately gefitinib and the chemotherapeutic alternatives to 3WD. The cumulative odds ratio was 0.927 (P=0.313) for 1-year SR, 0.889 (P=0.323) for the chemotherapeutic alternatives to 3WD and 0.953 (P=0.616) for gefitinib. The experimental arms showed a significant advantage in quality of life in the cumulative analysis (odds ratio=1.623, P=0.01) and in the subgroup of patients treated with gefitinib (odds ratio=1.962, P

KW - docetaxel

KW - erlotinib

KW - gefitinib

KW - lung cancer

KW - pemetrexed

KW - second-line treatments

KW - topotecan

UR - http://www.scopus.com/inward/record.url?scp=84870245919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870245919&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31822dfd13

DO - 10.1097/COC.0b013e31822dfd13

M3 - Article

VL - 35

SP - 593

EP - 599

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -